Get notified of page updates
Education > XRAY > Search Results

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search by Topic Submit an Article for Review

All XRAYs

11 through 20 of 310

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

Study : H. pylori bacteria infection and risk of stomach cancer in mutation carriers

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

Most relevant for: People who are at increased risk for stomach cancer due to an inherited mutation.

The results of a study in Japan show that people with a bacterial infection called H. pylori and an inherited mutation in an ATM, BRCA1, BRCA2 or PALB2 gene have a high risk of stomach cancer.   (Posted 1/19/24)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Benefit of pancreatic cancer screening

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with an inherited BRCA1 or BRCA2 mutation

Among people with an inherited mutation in a BRCA1 or BRCA2 gene, screening for pancreatic cancer found most cancers at an earlier stage when they could be treated by surgery. Posted 1/17/24)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

Study : Genes, genetic counseling and disparities in endometrial cancer

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

Most relevant for: People diagnosed with endometrial cancer

Endometrial cancer is on the rise, and it can run in families. Genetic counseling has benefits for people with cancer and their family members. However, Black women with endometrial cancer more often have worse outcomes than white women.  Black women with endometrial cancer who test positive for an inherited mutation are less likely to see a genetic counselor. Given these disparities, Black women would benefit from better access to and referrals for genetic counseling. (Posted 12/14/23)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Immunotherapy improves outcomes of advanced endometrial cancer

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with advanced endometrial cancer

Standard treatment for advanced endometrial cancer may soon change. A study found that people with advanced or recurrent endometrial cancer who received immunotherapy with chemotherapy had better outcomes than those who had chemotherapy alone. (Posted 12/4/23)

Este artículo está disponible en español.

Read More

Relevance: Medium

Article : Breast cancer risk for transgender women with inherited mutations

Relevance: Medium

Most relevant for: Transgender women with inherited mutations who are considering or have had gender affirming care

There has been little research on breast cancer risk for transgender women who are at high risk for breast cancer due to an inherited mutation. This review summarizes what we know. (Posted 11/29/23)

Este artículo está disponible en español.

Read More

Relevance: High

Quality of Writing: High

Article : Signs of endometrial cancer: Six survivor stories

Relevance: High

Quality of Writing: High

Most relevant for: Women who want to learn more about the signs of or are at risk for endometrial cancer.

This article shares the experiences of six women diagnosed with endometrial cancer. It highlights the most common signs of endometrial cancer.  (Posted 11/16/23)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Update : New drug combination approved for treatment of BRCA-mutated metastatic prostate cancer

Relevance: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with metastatic castration resistant prostate cancer with a mutation in BRCA1 or BRCA2

The FDA approved Akeega (niraparib and abiraterone) plus prednisone for the treatment of BRCA-mutated, metastatic castration-resistant prostate cancer (mCRPC). Akeega can be used as an early or later treatment. (Posted 11/9/23)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Pausing hormone therapy to pursue pregnancy does not increase the short-term risk of early-stage cancer recurrence

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Women with breast cancer who are considering pregnancy

Women who paused hormone therapy treatment of early-stage hormone receptor-positive (HR-positive) breast cancer to attempt to get pregnant had no increase in short-term recurrence. (Posted 11/3/23)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

View Related Clinical Trials

Article : Red flags for colorectal cancer in young adults

Relevance: Medium-High

Strength of Science: Medium-High

View Related Clinical Trials

Most relevant for: Young adults

The rate of colorectal cancer in young adults has been increasing. Researchers in this study identified four signs or “red flags” for colorectal cancer before age 50 (considered to be early onset colorectal cancer). Recognizing these red flags can help diagnose and treat colorectal cancer earlier.  (Posted 10/23/23)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Update : New first-line treatment option for metastatic prostate cancer

Relevance: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with metastatic castration resistant prostate cancer who have an inherited or tumor mutation in certain genes.

The FDA has approved Talzenna (talazoparib) with Xtandi (enzalutamide) as first-line treatments for some patients with metastatic castration-resistant prostate cancer. (Posted 10/2/23)

Este artículo está disponible en español.

Read More